BGT — Bio-Gene Technology Cashflow Statement
0.000.00%
Last trade - 00:00- AU$5.02m
- AU$3.08m
- AU$0.49m
Annual cashflow statement for Bio-Gene Technology, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | AAS | AAS | AAS | AAS | AAS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.054 | 0.086 | 0.087 | 0.04 | 0.618 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.99 | -3.28 | -2.75 | -2.54 | -1.94 |
| Capital Expenditures | -0.007 | 0 | -0.006 | 0 | 0 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | 0 | — | — | — |
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.007 | 0 | -0.006 | 0 | 0 |
| Financing Cash Flow Items | -0.236 | 0 | -0.055 | -0.076 | -0.196 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.41 | -0.075 | 1.98 | 1.47 | 2.74 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.41 | -3.35 | -0.781 | -1.07 | 0.801 |